<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04302220</url>
  </required_header>
  <id_info>
    <org_study_id>2019KYPJ079</org_study_id>
    <nct_id>NCT04302220</nct_id>
  </id_info>
  <brief_title>Myopic Optic Neuropathy in Chinese High Myopia Population</brief_title>
  <official_title>Natural History of Myopic Optic Neuropathy for High Myopia in Chinese Adult Population: a Registry Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study intends to establish a registry cohort to enroll patients with high myopia to
      study the natural course of myopic optic neuropathy in Chinese adult population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Global prevalence of high myopia brings about markedly increasing of blinding complications
      as myopic optic neuropathy (MON) and glaucoma. It was estimated that there were 163 million
      people who have high myopia in 2000, and the population with high myopia would increase to
      almost one billion (9.8% of the world population) worldwide by 2050.

      Glaucoma is the leading cause of irreversible blindness worldwide while it is difficult to
      distinguish glaucoma among MON in high myopia eyes. However, there lack longitudinal study to
      illustrate the natural course interpreting the distribution and natural history of MON.

      In view of the above problems, this is a longitudinal registry cohort study to observe the
      long-term changes of structural and functional parameters of MON in high myopia, and to
      investigate the natural course and associted risk factors that influence the progression in a
      Chinese adult population.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 6, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>Progression of glaucoma within 36 months</measure>
    <time_frame>3 years</time_frame>
    <description>Structural and functional changes of glaucoma using visual field, stereoscopic fundus photography.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression of myopia and other structural changes of retina and choroid.</measure>
    <time_frame>3 years</time_frame>
    <description>Structural and functional changes of myopia based on axial length and refractive error.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">813</enrollment>
  <condition>Eye Diseases</condition>
  <arm_group>
    <arm_group_label>high myopia</arm_group_label>
    <description>Population who have high myopia.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Saliva smple.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who have high myopia aged from 18 to above.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Age ≥18 years

          -  Equivalent spherical ≤-6D or axial length ≥26.5mm

          -  Best corrected visual acuity ≥ 6/12

        Exclusion Criteria

          -  Unwilling or unable to give consent, or unable to return for scheduled protocol
             visits.

          -  Glaucoma secondary to penetrating keratoplasty, trauma, steroids, retinal
             disease/surgery, or neovascular disease.

          -  Obvious corneal and iris lesions, or severe cataracts interfering with fundus
             examinations, VF test or monophthalmia.

          -  Need for ocular surgery/laser or anticipated need for cataract surgery during the
             study period.

          -  Other serious systemic diseasesf (i.e. hypertension, heart disease, diabetes, or
             rheumatic immune system diseases);

          -  Pregnant or nursing women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiulan Zhang, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhongshan Ophthalmic Center, Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiulan Zhang, MD, PhD</last_name>
    <phone>+86 13570166308</phone>
    <email>zhangxl2@mail.sysu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zhongshan Ophthalmic Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiulan Zhang, MD, PhD</last_name>
      <phone>8613570166308</phone>
      <email>zhangxl2@mail.sysu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 7, 2020</study_first_submitted>
  <study_first_submitted_qc>March 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 10, 2020</study_first_posted>
  <last_update_submitted>March 26, 2020</last_update_submitted>
  <last_update_submitted_qc>March 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Xiulan Zhang</investigator_full_name>
    <investigator_title>Professor of Ophthalmology, Director of Clinical Research Center, Director of CFDA-certified Pharmaceutical Research Unit, State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center</investigator_title>
  </responsible_party>
  <keyword>myopic optic neuropathy</keyword>
  <keyword>high myopia</keyword>
  <keyword>glaucoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Optic Nerve Diseases</mesh_term>
    <mesh_term>Myopia</mesh_term>
    <mesh_term>Eye Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

